Skip to main content

29-06-2017 | Oncology | News | Article

ASCO 2017 in brief

Routine detection of actionable mutations feasible, but benefit limited to a few

medwireNews: ProfiLER-01 study data suggest that high-throughput genomic testing can be incorporated into routine practice, but only a subset of patients derive a clinical benefit.

Next-generation sequencing of a panel of 69 cancer-related genes and whole-genome comparative genomic hybridization identified an actionable alteration – defined as one that can theoretically be matched to a targeted agent under investigation or currently available – in just over half (52%) of 1944 patients with advanced cancer, most commonly breast cancer (20%).

But of the 676 (35%) patients for whom a multidisciplinary molecular tumor board recommended targeted therapies, only 143 (7%) received such treatment.

Presenting the findings at the 2017 annual meeting of the American Society of Clinical Oncology in Chicago, Illinois, USA, Olivier Tredan (Centre Léon Bérard, Lyon, France) highlighted that overall survival was better for those who did versus those who did not receive the recommended therapy, with 3-and 5-year rates of 53.7% versus 46.1% and 34.8% versus 28.1%, respectively.

However, poor health and/or rapid progression were among the reasons for not receiving treatment, he noted.

Tredan concluded that although such routine testing is feasible, “screening heavily-pretreated advanced cancer patients limits the number of patients who can actually receive treatment.”

One of the next steps, he added, is to explore such screening in an earlier setting.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group